Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 10;11:697967. doi: 10.3389/fonc.2021.697967

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zaryouh, De Pauw, Baysal, Pauwels, Peeters, Vermorken, Lardon and Wouters

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Protein levels of total and phosphorylated Akt1/2/3 in cetuximab sensitive (SC263-S and SCC22b-S) HNSCC cell lines and corresponding acquired cetuximab resistant (SC263-R and SCC22b-R) variants. (A) Western blot was used to determine the levels of total and phosphorylated Akt1/2/3 (S473) after cetuximab treatment in cetuximab sensitive and acquired cetuximab resistant HNSCC cell lines. β-actin detection served as loading control. (B) Quantification of western blot results for total and phosphorylated Akt1/2/3. Signals were corrected for β-actin and the effect of cetuximab treatment is presented as fold change. Fold changes were calculated by dividing the mean fluorescent signal of the treatment and control groups. The graph represents the average fold change of three independent experiments. (C) Fold change of phosphorylated Akt1/2/3 at S473 following cetuximab treatment observed with protein phosphorylation profiling and western blot. CET, cetuximab; pAkt1/2/3, phosphorylated Akt1/2/3; *p-value ≤ 0.050. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.